$ACIU News

AC Immune Announces Three Presentations At The Alzheimer's Association International Conference, July 12-15

AC Immune: Holding Into A Make-Or-Break H2 2026 Readout

AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts

AC Immune Gets $4M Grant for Parkinson's Trial Extension

AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral Sclerosis

BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

AC Immune Q1 EPS $(0.19) Beats $(0.20) Estimate, Sales $1.429M Beat $1.000M Estimate

AC Immune Announces It Dosed The First Patients In Cohort AD4 In The Ongoing Phase 1b/2 ABATE Trial

AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts

AC Immune shares are trading higher after BTIG reiterated its Buy rating on the stock and maintained a $8 price target.

BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

AC Immune Q4 EPS $(0.17) Beats $(0.19) Estimate, Sales $422.914K

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS

Retail investors are AC Immune SA's (NASDAQ:ACIU) biggest owners and were rewarded after market cap rose by US$53m last week

Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

AC Immune posts positive data for Parkinson’s immunotherapy

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease